Answers are grounded in this paper and cite their sources.
This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the efficacy and safety of long‐acting aripiprazole (depot) compared with placebo for people with schizophrenia.
No takes yet. Share an insight, caveat, or question.
Hodgson et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: